LAKE LAKELAND INDUSTRIES INC
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 798081 · Fiscal year ends 01/31
Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.3%
TTM net income YoY-24.3%
TTM EPS YoY1.4%
Revenue 3-yr CAGR17.0%
Net income 3-yr CAGR—
Margins
Gross margin32.6%
Operating margin-4.1%
Net margin-14.0%
FCF margin-0.3%
EBITDA margin-2.5%
Returns
ROE-19.6%
ROA-12.3%
ROIC (approx.)-4.7%
Asset turnover0.88x
Leverage & solvency
Liabilities / assets39.4%
Debt / equity0.23x
Current ratio2.98x
Interest coverage-3.50x
Cash quality & payout
Operating cash flow / net income0.03x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue-0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-01-31 | FY20252025-01-31 |
|---|---|---|
| Income statement | ||
| Revenue | $192.65M | $167.21M |
| Cost of revenue | $129.32M | $98.54M |
| Gross profit | $63.33M | $68.67M |
| Operating income | -$15.51M | -$9.27M |
| Interest expense | $2.15M | $1.65M |
| Pretax income | -$17.70M | -$18.36M |
| Income tax | $7.61M | -$281,000 |
| Net income | -$25.31M | -$18.07M |
| EBITDA | -$12.71M | -$6.67M |
| EPS (basic) | -2.63 | -2.43 |
| EPS (diluted) | -2.63 | -2.43 |
| Weighted avg. shares (diluted) | 9.63M | 7.43M |
| Balance sheet | ||
| Cash & equivalents | $12.52M | $17.48M |
| Receivables | $32.04M | $27.61M |
| Inventory | $82.54M | $82.74M |
| Current assets | $134.19M | $136.53M |
| PP&E, net | $11.64M | $13.95M |
| Goodwill | $15.29M | $16.24M |
| Intangibles | $31.72M | $25.50M |
| Total assets | $209.93M | $212.53M |
| Current liabilities | $37.96M | $34.91M |
| Short-term debt | $1.89M | $939,000 |
| Long-term debt | $30.38M | $16.43M |
| Total debt | $32.27M | $17.36M |
| Total liabilities | $80.81M | $65.91M |
| Shareholders' equity | $129.13M | $146.63M |
| Net debt | $19.76M | -$111,000 |
| Shares outstanding | 9.81M | 9.50M |
| Cash flow statement | ||
| Operating cash flow | -$15.75M | -$15.88M |
| Capital expenditure | $671,000 | $1.54M |
| Free cash flow | -$16.42M | -$17.42M |
| Investing cash flow | -$1.18M | -$47.74M |
| Financing cash flow | $12.51M | $56.59M |
| Depreciation & amortization | $2.80M | $2.60M |
| Stock-based compensation | $3.39M | $1.56M |
| Dividends paid | $1.15M | $887,000 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.